Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Total Liabilities (2016 - 2025)

Perspective Therapeutics' Total Liabilities history spans 15 years, with the latest figure at $52.6 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 16.07% year-over-year to $52.6 million; the TTM value through Sep 2025 reached $52.6 million, down 16.07%, while the annual FY2024 figure was $50.4 million, 122.05% up from the prior year.
  • Total Liabilities for Q3 2025 was $52.6 million at Perspective Therapeutics, up from $45.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $62.7 million in Q3 2024 and bottomed at $2.9 million in Q4 2021.
  • The 5-year median for Total Liabilities is $11.5 million (2023), against an average of $22.7 million.
  • The largest annual shift saw Total Liabilities skyrocketed 558.51% in 2023 before it decreased 16.07% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $2.9 million in 2021, then grew by 20.55% to $3.4 million in 2022, then surged by 558.51% to $22.7 million in 2023, then skyrocketed by 122.05% to $50.4 million in 2024, then grew by 4.31% to $52.6 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Total Liabilities are $52.6 million (Q3 2025), $45.0 million (Q2 2025), and $44.7 million (Q1 2025).